These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 32063110)

  • 21. A phase II study of pazopanib as front-line therapy in patients with non-resectable or metastatic soft-tissue sarcomas who are not candidates for chemotherapy.
    Hirbe AC; Eulo V; Moon CI; Luo J; Myles S; Seetharam M; Toeniskoetter J; Kershner T; Haarberg S; Agulnik M; Monga V; Milhem M; Parkes A; Robinson S; Okuno S; Attia S; Van Tine BA
    Eur J Cancer; 2020 Sep; 137():1-9. PubMed ID: 32712457
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Differences in the Efficacies of Pazopanib and Gemcitabine/Docetaxel as Second-Line Treatments for Metastatic Soft Tissue Sarcoma.
    Kim JH; Park HS; Heo SJ; Kim SK; Han JW; Shin KH; Kim SH; Hur H; Kim KS; Choi YD; Kim S; Lee YH; Suh JS; Ahn JB; Chung HC; Noh SH; Rha SY; Kim HS
    Oncology; 2019; 96(2):59-69. PubMed ID: 30336470
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hypertension (HTN) as a potential biomarker of efficacy in pazopanib-treated patients with advanced non-adipocytic soft tissue sarcoma. A retrospective study based on European Organisation for Research and Treatment of Cancer (EORTC) 62043 and 62072 trials.
    Duffaud F; Sleijfer S; Litière S; Ray-Coquard I; Le Cesne A; Papai Z; Judson I; Schöffski P; Chawla SP; Dewji R; Marreaud S; Verweij J; van der Graaf WT
    Eur J Cancer; 2015 Nov; 51(17):2615-23. PubMed ID: 26321011
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy of Pazopanib in patients with metastatic uterine sarcoma: A multi-institutional study.
    Sunar V; Korkmaz V; Akin S; Can Guven D; Arik Z; Ates O; Yilmaz M; Mutlu Meydanli M; Oksuzoglu B
    J BUON; 2019; 24(6):2327-2332. PubMed ID: 31983102
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pazopanib for treatment of advanced extraskeletal myxoid chondrosarcoma: a multicentre, single-arm, phase 2 trial.
    Stacchiotti S; Ferrari S; Redondo A; Hindi N; Palmerini E; Vaz Salgado MA; Frezza AM; Casali PG; Gutierrez A; Lopez-Pousa A; Grignani G; Italiano A; LeCesne A; Dumont S; Blay JY; Penel N; Bernabeu D; de Alava E; Karanian M; Morosi C; Brich S; Dagrada GP; Vallacchi V; Castelli C; Brenca M; Racanelli D; Maestro R; Collini P; Cruz J; Martin-Broto J
    Lancet Oncol; 2019 Sep; 20(9):1252-1262. PubMed ID: 31331701
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A randomized, double-blind, placebo-controlled, Phase III study of pazopanib in patients with soft tissue sarcoma: results from the Japanese subgroup.
    Kawai A; Araki N; Hiraga H; Sugiura H; Matsumine A; Ozaki T; Ueda T; Ishii T; Esaki T; Machida M; Fukasawa N
    Jpn J Clin Oncol; 2016 Mar; 46(3):248-53. PubMed ID: 26864131
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pazopanib monotherapy in the treatment of pretreated, metastatic uterine sarcoma: a single-center retrospective study.
    Kim HJ; Kim Y; Lee SJ; Lee J; Park SH
    J Gynecol Oncol; 2018 Jan; 29(1):e3. PubMed ID: 29185261
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Balancing Prolonged Survival with QoL Using Low-dose Pazopanib Maintenance: A Comparison with the PALETTE Study.
    Abe K; Yamamoto N; Hayashi K; Takeuchi A; Miwa S; Inatani H; Higuchi T; Taniguchi Y; Tsuchiya H
    Anticancer Res; 2016 Jun; 36(6):2893-7. PubMed ID: 27272802
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pazopanib in advanced vascular sarcomas: an EORTC Soft Tissue and Bone Sarcoma Group (STBSG) retrospective analysis.
    Kollár A; Jones RL; Stacchiotti S; Gelderblom H; Guida M; Grignani G; Steeghs N; Safwat A; Katz D; Duffaud F; Sleijfer S; van der Graaf WT; Touati N; Litière S; Marreaud S; Gronchi A; Kasper B
    Acta Oncol; 2017 Jan; 56(1):88-92. PubMed ID: 27838944
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Postmarketing observational study of pazopanib in patients with metastatic soft tissue sarcoma in Japan.
    Teshima Y; Nomura S; Fukasawa N
    Jpn J Clin Oncol; 2021 Apr; 51(4):612-621. PubMed ID: 33283234
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pazopanib and soft-tissue sarcomas. Too toxic.
    Prescrire Int; 2013 Jun; 22(139):145-7. PubMed ID: 23866345
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pazopanib, a new therapy for metastatic soft tissue sarcoma.
    Verweij J; Sleijfer S
    Expert Opin Pharmacother; 2013 May; 14(7):929-35. PubMed ID: 23488774
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Association of pazopanib-induced toxicities with outcome of patients with advanced soft tissue sarcoma; a retrospective analysis based on the European Organisation for Research and Treatment of Cancer (EORTC) 62043 and 62072 clinical trials.
    Vos M; Sleijfer S; Litière S; Touati N; Duffaud F; van der Graaf WT; Gelderblom H
    Acta Oncol; 2019 Jun; 58(6):872-879. PubMed ID: 30831041
    [No Abstract]   [Full Text] [Related]  

  • 34. Randomized Comparison of Pazopanib and Doxorubicin as First-Line Treatment in Patients With Metastatic Soft Tissue Sarcoma Age 60 Years or Older: Results of a German Intergroup Study.
    Grünwald V; Karch A; Schuler M; Schöffski P; Kopp HG; Bauer S; Kasper B; Lindner LH; Chemnitz JM; Crysandt M; Stein A; Steffen B; Richter S; Egerer G; Ivanyi P; Zimmermann S; Liu X; Kunitz A
    J Clin Oncol; 2020 Oct; 38(30):3555-3564. PubMed ID: 32840417
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Surrogacy of intermediate endpoints for overall survival in randomized controlled trials of first-line treatment for advanced soft tissue sarcoma in the pre- and post-pazopanib era: a meta-analytic evaluation.
    Tanaka K; Kawano M; Iwasaki T; Itonaga I; Tsumura H
    BMC Cancer; 2019 Jan; 19(1):56. PubMed ID: 30634944
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Exposure-survival analyses of pazopanib in renal cell carcinoma and soft tissue sarcoma patients: opportunities for dose optimization.
    Verheijen RB; Swart LE; Beijnen JH; Schellens JHM; Huitema ADR; Steeghs N
    Cancer Chemother Pharmacol; 2017 Dec; 80(6):1171-1178. PubMed ID: 29051995
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pazopanib for treatment of advanced malignant and dedifferentiated solitary fibrous tumour: a multicentre, single-arm, phase 2 trial.
    Martin-Broto J; Stacchiotti S; Lopez-Pousa A; Redondo A; Bernabeu D; de Alava E; Casali PG; Italiano A; Gutierrez A; Moura DS; Peña-Chilet M; Diaz-Martin J; Biscuola M; Taron M; Collini P; Ranchere-Vince D; Garcia Del Muro X; Grignani G; Dumont S; Martinez-Trufero J; Palmerini E; Hindi N; Sebio A; Dopazo J; Dei Tos AP; LeCesne A; Blay JY; Cruz J
    Lancet Oncol; 2019 Jan; 20(1):134-144. PubMed ID: 30578023
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma (REGOSARC): a randomised, double-blind, placebo-controlled, phase 2 trial.
    Mir O; Brodowicz T; Italiano A; Wallet J; Blay JY; Bertucci F; Chevreau C; Piperno-Neumann S; Bompas E; Salas S; Perrin C; Delcambre C; Liegl-Atzwanger B; Toulmonde M; Dumont S; Ray-Coquard I; Clisant S; Taieb S; Guillemet C; Rios M; Collard O; Bozec L; Cupissol D; Saada-Bouzid E; Lemaignan C; Eisterer W; Isambert N; Chaigneau L; Cesne AL; Penel N
    Lancet Oncol; 2016 Dec; 17(12):1732-1742. PubMed ID: 27751846
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Activity of Pazopanib and Trabectedin in Advanced Alveolar Soft Part Sarcoma.
    Stacchiotti S; Mir O; Le Cesne A; Vincenzi B; Fedenko A; Maki RG; Somaiah N; Patel S; Brahmi M; Blay JY; Boye K; Sundby Hall K; Gelderblom H; Hindi N; Martin-Broto J; Kosela H; Rutkowski P; Italiano A; Duffaud F; Kobayashi E; Casali PG; Provenzano S; Kawai A
    Oncologist; 2018 Jan; 23(1):62-70. PubMed ID: 28754721
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A double-blind placebo-controlled randomized phase II trial assessing the activity and safety of regorafenib in non-adipocytic sarcoma patients previously treated with both chemotherapy and pazopanib.
    Penel N; Mir O; Wallet J; Ray-Coquard I; Le Cesne A; Italiano A; Salas S; Delcambre C; Bompas E; Bertucci F; Saada-Bouzid E; Chaigneau L; Chevreau C; Brodowicz T; Decoupigny E; Vanseymortier M; Laroche L; Taieb S; Le Deley MC; Blay JY
    Eur J Cancer; 2020 Feb; 126():45-55. PubMed ID: 31918233
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.